Rank #1: Detangling Difficult Conversations About Multiple Sclerosis: Clinical Exchanges
Valid until: 24-04-2020
Claim your CME credit at https://reachmd.com/programs/cme/detangling-difficult-conversations-about-multiple-sclerosis-clinical-exchanges/10627/
Multiple sclerosis (MS) is one of the leading causes of disability worldwide. As the treatment armamentarium continues to grow, patient involvement in the development of an effective treatment strategy is becoming increasingly important. In this Clinical ExchangesSM activity, leading MS specialists discuss issues of diagnosing MS, initiating treatment, and switching therapies, all in the context of practical shared decision-making techniques demonstrated by their own patients.
Apr 25 2019
Rank #2: New Insights on Treating Diabetic Retinopathy & Diabetic Macular Edema from the 2018 AAO Meeting
Valid until: 21-12-2019
Claim your CME credit at https://reachmd.com/programs/cme/new-insights-treating-diabetic-retinopathy-diabetic-macular-edema-2018-aao-meeting/10580/
Presented by the Johns Hopkins University School of Medicine.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Recent data, including those presented at the 2018 American Academy of Ophthalmology annual meeting, regarding the use of intravitreal anti-VEGF agents in patients with diabetic macular edema (DME) and diabetic retinopathy (DR), have the potential to shift treatment strategies by offering a therapy option that may prevent progression in earlier stages of disease. However, as ongoing research continues to evolve, it can be challenging for ophthalmologists and retina specialists to remain up-to-date on these findings and interpret their impact on patient management. This activity will not only provide an overview of the most current data on anti-VEGF treatments in patients with DR and DME, it will also evaluate potential clinical implications that can assist practicing clinicians in translating the results of this research into real-world patient care.
Dec 21 2018
Rank #3: IBS-D: What to Do when Typical Treatment Methods Fail
Valid until: 14-12-2019
Claim your CME credit at https://reachmd.com/programs/cme/ibs-d-what-to-do-when-typical-treatment-methods-fail/10428/
Patients with IBS-D often try multiple medications that fail to treat their symptoms. IBS has a heterogeneous pathogenesis, and there are no specific algorithms for treatment subtypes. In this activity, clinicians will learn treatment options to consider for patients with IBS-D in whom some previous therapies have failed.
Dec 14 2018
Rank #4: Bleeding Disorders & Female Patients: Optimizing Care in Women’s Health Settings
Valid until: 14-01-2020
Claim your CME credit at https://reachmd.com/programs/cme/bleeding-disorders-and-female-patients-optimizing-care-womens-health-settings/10598/
Women with bleeding disorders, including hemophilia carriers and those with Von Willebrand disease (VWD), or VWD are disproportionately affected by bleeding when compared to men, largely due to menstruation and pregnancy. In this CME activity, discover how women’s healthcare providers can make a significant impact in these patients’ lives by facilitating early identification, beginning management, and working with a multidisciplinary team to ultimately provide the best care to our patients.
Dr. Andrea Singer welcomes Dr. Ayesha Zia to discuss these cases and more.
Dec 14 2018
Rank #5: cSCC Patient Clinic
Valid until: 05-05-2020
Claim your CME credit at https://reachmd.com/programs/cme/cscc-patient-clinic/10617/
Available treatment options for cutaneous squamous cell carcinoma (cSCC) are expanding and involving more interdisciplinary dialogue. This slides/audio presentation features 3 clinical case scenarios with feedback and commentary by a medical oncologist, surgeon, and dermatologist exploring topics in immunotherapy, Mohs surgery, and complex patient presentations.
May 06 2019
Rank #6: Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease
Valid until: 14-12-2019
Claim your CME credit at https://reachmd.com/programs/cme/iron-deficiency-anemia-patients-inflammatory-bowel-disease/10568/
As the most common extraintestinal complication from IBD, iron deficiency anemia (IDA) can take a heavy toll on your patients’ quality of life. This activity will review those impacts, in addition to discussing the different therapies and resources that are available to both you and your IBD patients.
Dec 14 2018
Rank #7: Mild to Moderate Acne in Primary Care: A Multidisciplinary Discussion
Valid until: 14-12-2019
Claim your CME credit at https://reachmd.com/programs/cme/mild-moderate-acne-primary-care-multidisciplinary-discussion/10574/
Particularly among adolescent patients, treating acne is a top concern, which is why primary care physicians need to dedicate time to have this discussion with their patients. To help you develop the best management plan, this activity will cover treatment options based on acne severity along with tips for improving patient adherence.
Dec 14 2018
Rank #8: Distilling Modern Medical Approaches in Advanced NSCLC: Precision, Performance, & Parallels with Patients
Valid until: 12-05-2020
Claim your CME credit at https://reachmd.com/programs/cme/distilling-modern-medical-approaches-in-advanced-nsclc-precision-performance-and-parallels/10775/
Lung and bronchus cancer remain the leading cause of cancer-related deaths in the United States among both men and women. The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, the anaplastic lymphoma kinase (ALK) fusion oncogene, ROS1 gene rearrangements, and BRAF has led to an improvement in overall survival and progression-free survival by identifying subgroups of patients who benefit from targeted treatment; however, most NSCLC tumors lack these mutations.
NSCLC is a highly active research area and its treatment is rapidly evolving. The algorithm for the treatment of metastatic NSCLC has become increasingly complex as new therapies are being developed, including advances in the treatment of patients with metastatic NSCLC without targetable activating mutations that has progressed on prior platinum-based therapy, or chemotherapy in combination with immunotherapy, including NSCLC that has progressed rapidly on initial therapy.
Through real-world clinical cases, this activity will review available treatment options and guideline recommendations for patients with advanced NSCLC without targetable activating mutations that has progressed on initial platinum-based therapy, or immunotherapy combined with chemotherapy, and available data that can inform treatment of NSCLC that progresses rapidly on initial therapy. Discussion will include real-world patient ...
May 13 2019
Rank #9: Real-World Treatment Effectiveness Compared with Clinical Trial Efficacy in Multiple Myeloma: A Focus on the EU
Valid until: 08-05-2020
Claim your CME credit at https://reachmd.com/programs/cme/real-world-treatment-effectiveness-compared-clinical-trial-efficacy-multiple-myeloma-focus-eu/10772/
Substantial improvements in survival have been seen in patients with multiple myeloma (MM) thanks to the introduction of multiple novel agents and regimens. However, these therapies and approaches may have limitations due to the differences in well-controlled, patient-restricted clinical trials and real-world settings. And since this discrepancy has already been seen firsthand in the EU, it’s essential that clinicians fully anticipate the real-world effectiveness of approved treatments for MM so they can optimize outcomes for their patients.
May 09 2019
Rank #10: Diagnosis & Treatment of Diabetic Macular Edema
Valid until: 23-01-2020
Claim your CME credit at https://reachmd.com/programs/cme/diagnosis-and-treatment-diabetic-macular-edema/10252/
Diabetic retinopathy is becoming increasingly more common as an obesity epidemic spreads around the world. It’s now the major cause of vision loss for working-age adults. This activity will discuss the current DRCR.net algorithms for diagnosing and treating diabetic macular edema as well as the results of the Protocol T study which compared several anti-VEGF agents.
Jan 23 2019
Rank #11: IBS-D: The Role of Pathophysiology in Assessment & Treatment
Valid until: 14-12-2019
Claim your CME credit at https://reachmd.com/programs/cme/ibs-d-the-role-of-pathophysiology-in-assessment-and-treatment/10427/
Patients with IBS-D may spend years before they are accurately diagnosed, with their symptoms often being labeled as psychosomatic. Considering the potential underlying cause of IBS-D can help guide diagnosis as well as the choice of appropriate treatment. In this activity, clinicians will learn screening methods and factors in the pathophysiology of IBS-D to more accurately diagnosis patients and select appropriate treatment, along with patient-clinician communication strategies that can improve outcomes.
Dec 14 2018
Rank #12: Keys to Detecting COPD in the Primary Care Setting
Valid until: 02-11-2020
Claim your CME credit at https://reachmd.com/programs/cme/keys-to-detecting-copd-in-the-primary-care-setting/10940/
Due to comorbidities that often complicate the diagnosis of chronic obstructive pulmonary disease (COPD), this complex disease can often be missed in the clinic. To stress the importance of early recognition and to share their experiences with diagnosing and managing COPD, Dr. Jennifer Caudle is joined by Chief Science Officer for the COPD Foundation and primary care physician Dr. Barbara Yawn, Chief Medical Officer for the COPD Foundation and pulmonologist Dr. Byron Thomashow, and Mr. Doug Martin, a patient with COPD.
Nov 02 2019
Rank #13: Emerging Considerations in Triple-Negative Breast Cancer: Focus on Immunotherapy
Valid until: 01-11-2020
Claim your CME credit at https://reachmd.com/programs/cme/emerging-considerations-triple-negative-breast-cancer-focus-immunotherapy/11031/
Immunotherapy-based combination approaches are changing the standard of care for certain patients with triple-negative breast cancer. Dr. Sara Hurvitz and Dr. Tiffany Traina are here to discuss these advances in treatment and what they mean for patient care.
Nov 01 2019
Rank #14: HIV Can Be Prevented—Are You Doing Your Part?
Valid until: 29-10-2020
Claim your CME credit at https://reachmd.com/programs/cme/hiv-can-be-prevented-are-you-doing-your-part/10993/
More than 1.1 million Americans are living with HIV, and yet 162,500 are unaware of their diagnosis. With 40 percent of new infections being transmitted by people who are living with undiagnosed HIV, providers can have an effect on decreasing that rate by increasing testing and education and by identifying patients who are candidates for preexposure prophylaxis (PrEP).
Oct 29 2019
Rank #15: Rapid Start ART — A New Model for HIV Care
Valid until: 29-10-2020
Claim your CME credit at https://reachmd.com/programs/cme/rapid-start-art-a-new-model-for-hiv-care/10994/
When encountering a patient who has newly diagnosed HIV, primary care clinicians typically refer the patient for specialist care. However, these patients don’t always initiate treatment in a timely manner and are at risk for transmitting the virus.
Fortunately, the rapid initiation of HIV antiretroviral therapy on the day of diagnosis or shortly thereafter may help these patients become virally suppressed more quickly than waiting to see a specialist, and to help clinicians who need guidance on how to rapidly initiate antiretroviral therapy, Drs. Isolde Butler and Charlene Flash offer their expertise.
Oct 29 2019
Rank #16: SERMs: Managing the Most Bothersome Symptoms of Menopause
Valid until: 25-10-2020
Claim your CME credit at https://reachmd.com/programs/cme/serms-managing-most-bothersome-symptoms-menopause/11038/
The genitourinary syndrome of menopause (GSM) is a collection of signs and symptoms associated with decreased estrogen and other sex steroids. And since at least half of the more than 64 million postmenopausal women in the US will be affected by GSM symptoms, this activity will discuss the role of selective estrogen receptor modulators (SERMs) in managing two of the most bothersome symptoms: dyspareunia and vaginal dryness.
Oct 25 2019
Rank #17: New Perspectives on Biologic Therapy in Crohn’s Disease
Valid until: 23-10-2020
Claim your CME credit at https://reachmd.com/programs/cme/new-perspectives-on-biologic-therapy-in-crohns-disease/11033/
Amid the ongoing dialogue on the shifting expectations of care in the management of Crohn's disease, Dr. Neil Nandi and Dr. Millie Long review the benefits of early initiation of biologics into the Crohn's disease treatment paradigm.
Oct 23 2019
Rank #18: Advances in the Management of Difficult-to-Treat Asthma
Valid until: 21-10-2020
Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-management-of-difficult-to-treat-asthma/10893/
The management of severe asthma has changed drastically after the introduction of biologics. However, their introduction comes with many questions, such as, When should they be used and in whom? This Care Team ForumSM brings pulmonologists and an allergist/immunologist in dialogue with a patient about the immunologic underpinning of asthma pathology and how it relates to identifying patients appropriate for step-up care with biologics.
Oct 22 2019
Rank #19: Connecting Science to Psoriatic Arthritis Patient Care
Valid until: 17-10-2020
Claim your CME credit at https://reachmd.com/programs/cme/connecting-science-psoriatic-arthritis-patient-care/10918/
Science is moving forward in understanding the key inflammatory pathways involved in psoriasis and psoriatic arthritis, which has led to the development of targeted, effective therapies for patients with these diseases. But with these advances, it’s becoming more and more important for clinicians to understand how to choose treatment options appropriately and how to discuss them with patients.
To explore the use of available treatments for psoriatic arthritis, Dr. Matt Birnholz sits down with Dr. Philip Mease and Dr. Allan Gibofsky.
Oct 17 2019
Rank #20: Increasing Awareness and Access to Spinal Muscular Atrophy Therapy
Valid until: 14-10-2020
Claim your CME credit at https://reachmd.com/programs/cme/increasing-awareness-and-access-spinal-muscular-atrophy-therapy/10992/
Spinal muscular atrophy (SMA) is a genetic disorder characterized by weakness in muscles and is caused by a loss of specialized nerve cells, called motor neurons, that control muscle movement. Since SMA significantly impacts both the quality of life and lifespan of those affected, this activity will describe the genetic basis for SMA and the various phenotypic expressions as well as improvements in accessing pharmacologic treatments for SMA.
Oct 14 2019